New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
05:55 EDTBSX, BSX, BSX, BSX, RNST, RNST, RNST, RNST, HBHC, HBHC, HBHC, HBHC, IBKC, IBKC, IBKC, IBKC, HOMB, HOMB, HOMB, HOMB, SFNC, SFNC, SFNC, SFNC, OZRK, OZRK, OZRK, OZRK, PNFP, PNFP, PNFP, PNFP, UCBI, UCBI, UCBI, UCBIStephens to host a field trip
Bank Field Trip travels through Memphis, New Orleans, Little Rock, Nashville and Atlanta on February 19-22.
News For BSX;RNST;HBHC;IBKC;HOMB;SFNC;OZRK;PNFP;UCBI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
08:16 EDTBSXBoston Scientific initiates PLATINUM Diversity trial
Subscribe for More Information
07:20 EDTBSXInternational Continence Society to hold annual meeting
ICS Annual Meeting 2014 is being held in Rio de Janeiro, Brazil on October 20-24.
07:11 EDTBSXAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
October 16, 2014
16:47 EDTUCBIUnited Community Banks raises dividend to 5c per share from 3c per share
Subscribe for More Information
16:32 EDTBSXBoston Scientific announces pacemaker CE mark with options for MRI
Boston Scientific has received CE Mark approval for the ACCOLADE pacemaker family. When implanted with the company's INGEVITY leads, ACCOLADE pacemakers are the first to enable patients to receive full-body MRI scans in both 1.5 Tesla and 3.0 Tesla systems. In addition, the Boston Scientific ImageReady technology offers the most flexible MRI options, allowing higher energy scan sequences, and featuring a programmable MRI timer designed to improve patient workflow. In addition to the CE mark approval and launch of the ACCOLADE pacemaker family, Boston Scientific received CE Mark approval for the VISIONIST and VALITUDE CRT-Ps with quadripolar pacing technology. When paired with the ACUITY X4 pacing leads, these systems offer many options to reach and pace the target location in the left ventricle, potentially improving the patient response to CRT therapy.
15:10 EDTBSXAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
10:01 EDTOZRKOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:19 EDTHOMBHome Bancshares reports Q3 EPS 41c, consensus 45c
Reports Q3 revenue $94.23M, consensus $93.34M. Book value per common share was $14.42 at September 30. Reports Q3 NII $78.61M.
06:02 EDTOZRKBank of the Ozarks upgraded to Buy from Hold at Wunderlich
Subscribe for More Information
October 15, 2014
09:42 EDTRNSTRenasant initiated with a Long-Term Buy at Hilliard Lyons
Subscribe for More Information
October 14, 2014
17:06 EDTOZRKBank of the Ozarks common stockholders’ equity was $876M at September 30
Subscribe for More Information
17:03 EDTOZRKBank of the Ozarks reports Q3 EPS 40c, consensus 39c
Subscribe for More Information
17:02 EDTOZRKBank of the Ozarks reports Q3 EPS 40c, consensus 39c
Subscribe for More Information
15:29 EDTOZRKNotable companies reporting after market close
Subscribe for More Information
October 13, 2014
15:24 EDTPNFP, RNSTNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Pinnacle Financial (PNFP), consensus 51c; GenCorp (GY), consensus 19c; Renasant (RNST), consensus 48c; Marten Transport (MRTN), consensus 25c; ShoreTel (SHOR), consensus 4c.
October 8, 2014
20:03 EDTBSXBoston Scientific confirms FDA panel votes for WATCHMAN device
After reviewing updated data and analysis for the Boston Scientific Corporation WATCHMAN Left Atrial Appendage Closure Device, the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee voted in favor of the Device. By a vote of 6 to 5, with 1 abstention, the panel concluded that the benefits of the WATCHMAN Device outweigh the potential risks. The panel voted that there is reasonable assurance that the device is safe, with a 12 yes to 0 no vote. On the question of reasonable assurance of effectiveness, the panel vote was unfavorable with a 6 yes to 7 no vote. The panel provided substantial input and guidance related to the proposed Indications for use and target patient population. There was widespread agreement among the panel members that the device provides a much needed alternative to long-term anticoagulation for some patients. While not bound by this vote, the FDA takes Advisory Panel comments and recommendations into account when reviewing the WATCHMAN Device application. The company is committed to working with the FDA to address the panel's comments.
18:42 EDTBSXBoston Scientific Watchman Device receives votes from FDA panel, Dow Jones says
The FDA Panel voted 6 to 5 that benefits of Boston Scientific's Watchman device outweigh the risks, Dow Jones reports. The panel voted 12 to 0 that the Watchman device is safe, and the panel voted 7 to 6 that the Watchman device is not effective, Dow Jones added.
15:25 EDTOZRKNotable companies reporting after market close
Subscribe for More Information
07:24 EDTBSXFDA Circulatory Systems Devices Panel to hold a meeting
The Committee discusses, makes recommendations and votes on information related to the Pre-Market Approval Application regarding Boston Scientific’s WATCHMAN Left Atrial Appendage (LAA) Closure Technology in a meeting being held in Gaithersburg, Maryland on October 8 at 8 am. Webcast Link
October 6, 2014
11:13 EDTBSXWells sees 60%-70% chance of positive FDA panel for Boston Scientific
After the FDA posted the briefing documents for the Watchman advisory committee meeting scheduled for October 8, Wells Fargo says it still believes chances of a positive panel and FDA approval are 60%-70%. The firm views the panel's focus on the "totality of data" is a positive signal. It has an Outperform rating on Boston Scientific.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use